Ollero M Dolores, Pineda Javier, Martínez de Esteban Juan Pablo, Toni Marta, Espada Mercedes, Anda Emma
Servicio de Endocrinología y Nutrición, Complejo Hospitalario de Navarra, Pamplona, Navarra, España; Instituto de Investigación Sanitaria de Navarra (IdisNa), Pamplona, Navarra, España.
Servicio de Endocrinología y Nutrición, Complejo Hospitalario de Navarra, Pamplona, Navarra, España; Instituto de Investigación Sanitaria de Navarra (IdisNa), Pamplona, Navarra, España.
Endocrinol Diabetes Nutr (Engl Ed). 2019 May;66(5):305-311. doi: 10.1016/j.endinu.2018.08.011. Epub 2018 Nov 16.
To determine the risk of hypothyroidism in pregnant women with autoimmune thyroid disease and thyrotropin (TSH) < 2,5 mIU/l at the beginning of pregnancy.
Prospective longitudinal study of pregnant women with no personal history of thyroid disease, and with TSH < 2.5 mIU/l in the first trimester. TSH, free thyroxine (FT4), anti peroxidase (TPO) and anti thyroglobulin antibodies were measured in the 3 trimesters of pregnancy. We compared thyroid function throughout pregnancy, and the development of gestational hypothyroidism (TSH >4 mIU/l) among pregnant women with positive thyroid autoimmunity and those with negative autoimmunity.
We included 300 pregnant women with mean baseline TSH 1.3 ± 0.6 mIU/l (9 gestational week). Positive thyroid autoinmunity was detected in 17.7% of women (n = 53) at the first trimester. Between the first and the third trimesters, TPO and anti thyroglobulin antibodies titers decreased 76.8% and 80.7% respectively. Thyroid function during pregnancy was similar among the group with positive autoimmunity and the group with negative autoimmunity, and the development of hypothyroidism was 1.9% (1/53) and 2% (5/247) respectively. Pregnant women in whom TSH increased above 4 mIU/l (n = 6), had higher baseline TSH levels compared to those who maintained TSH ≤4 mIU/l during pregnancy (1.8 vs. 1.3 mIU/l; p=.047).
In our population, women with TSH levels <2.5 mIU/l at the beginning of pregnancy have a minimal risk of developing gestational hypothyroidism regardless of thyroid autoimmunity.
确定妊娠初期患有自身免疫性甲状腺疾病且促甲状腺激素(TSH)<2.5 mIU/l的孕妇发生甲状腺功能减退的风险。
对无甲状腺疾病个人史且孕早期TSH<2.5 mIU/l的孕妇进行前瞻性纵向研究。在孕期三个阶段测量TSH、游离甲状腺素(FT4)、抗过氧化物酶(TPO)和抗甲状腺球蛋白抗体。我们比较了整个孕期的甲状腺功能,以及甲状腺自身免疫阳性和阴性的孕妇中妊娠期甲状腺功能减退(TSH>4 mIU/l)的发生情况。
我们纳入了300名孕妇,平均基线TSH为1.3±0.6 mIU/l(孕9周)。孕早期17.7%的女性(n = 53)检测到甲状腺自身免疫阳性。在孕早期和孕晚期之间,TPO和抗甲状腺球蛋白抗体滴度分别下降了76.8%和80.7%。甲状腺自身免疫阳性组和阴性组在孕期的甲状腺功能相似,甲状腺功能减退的发生率分别为1.9%(1/53)和2%(五分之二四七)。TSH升高至4 mIU/l以上的孕妇(n = 6)与孕期TSH≤4 mIU/l的孕妇相比,基线TSH水平更高(1.8对1.3 mIU/l;p = 0.047)。
在我们的研究人群中,妊娠初期TSH水平<2.5 mIU/l的女性,无论甲状腺自身免疫情况如何,发生妊娠期甲状腺功能减退的风险极小。